Howard Sofen

Professor Howard L. Sofen is addressing critical issues in dermatology, with a particular focus on the treatment of moderate-to-severe plaque psoriasis. As an HS Clinical Professor of Medicine at the Medicine University of California-San Francisco, he is renowned for his expertise in the field of dermatology. His research is dedicated to exploring the efficacy and safety of various medications for psoriasis, including innovative biologics such as tildrakizumab, deucravacitinib, and cedirogant. Professor Sofen's work is pivotal in advancing the understanding of how different treatments can improve the quality of life and disease management for psoriasis patients. He has contributed to numerous publications that delve into the impact of these treatments, providing valuable insights into their effectiveness and safety. His research is not only theoretical but also practical, as he is actively involved in clinical trials that evaluate the effectiveness of therapies like apremilast, ustekinumab, and ixekizumab in managing psoriasis symptoms. In addition to his research, Professor Sofen is committed to educating the next generation of dermatologists. His role as a clinical professor involves mentoring students and residents, sharing his extensive knowledge and experience in the field. His dedication to both research and education makes him a respected figure in the dermatology community. Professor Sofen's contributions extend beyond academia, as he collaborates with various organizations to promote awareness and understanding of psoriasis and its treatment. His work is instrumental in shaping the future of dermatological care, ensuring that patients receive the most effective and safe treatments available. Through his research and teaching, Professor Sofen continues to make significant strides in the field of dermatology, particularly in the management of psoriasis. His efforts are crucial in improving patient outcomes and advancing the overall understanding of this complex skin condition.